OR for individual clinical variables in the prediction of imminent cystic fibrosis (CF) pulmonary exacerbations (ie, <4 months post-stable visit)
| Clinical predictor | OR (95% CI) | p Value |
|---|---|---|
| Age (per year increase) | 1.01 (0.95 to 1.05) | 0.80 |
| Male (vs. female) | 1.20 (0.44 to 3.24) | 0.72 |
| Homozygous F508del (vs non-homozygous F508del) | 1.24 (0.47 to 3.29) | 0.67 |
| BMI (per kg/m2 increase) | 0.87 (0.75 to 1.02) | 0.08 |
| FEV1 (per % predicted increase) | 0.99 (0.97 to 1.00) | 0.13 |
| Sputum microbiology | ||
| MSSA | 0.79 (0.31 to 2.04) | 0.63 |
| MRSA | 0.63 (0.14 to 2.75) | 0.54 |
| Pseudomonas aeruginosa | 2.79 (1.05 to 7.40) | 0.04 |
| Stenotrophomonas maltophilia | 1.34 (0.08 to 22.4) | 0.84 |
| Burkholderia cepacia complex | 0.40 (0.08 to 2.16) | 0.29 |
| CF-related diabetes | 1.29 (0.35 to 4.75) | 0.70 |
| Exacerbation requiring intravenous antibiotics in prior year | 2.29 (0.83 to 6.34) | 0.11 |
| Current therapies | ||
| Inhaled antibiotics | 1.25 (0.42 to 3.75) | 0.69 |
| Oral azithromycin | 1.24 (0.47 to 3.29) | 0.67 |
BMI, body mass index; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive S. aureus.